Full-Life Technologies, a fully integrated global radiotherapeutics company, agreed to acquire Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer, for $245m. "The Focus-X acquisition perfectly leverages Full-Life's radiotechnology and development platform by adding two development ready compounds, including a lead with initial human data, a robust pipeline and world class peptide discovery capabilities," Lanny Sun, Full-Life Co-Founder, Chairman and CEO.